...
首页> 外文期刊>International journal of oncology >The flavonoid p-hydroxycinnamic acid mediates anticancer effects on MDA-MB-231 human breast cancer cells in vitro: Implications for suppression of bone metastases
【24h】

The flavonoid p-hydroxycinnamic acid mediates anticancer effects on MDA-MB-231 human breast cancer cells in vitro: Implications for suppression of bone metastases

机译:类黄酮对羟基肉桂酸在体外对MDA-MB-231人乳腺癌细胞介导抗癌作用:抑制骨转移的意义

获取原文
           

摘要

Tumor invasion into bone tissues is associated with osteoclast and osteoblast recruitment, resulting in the liberation of growth factors from the bone matrix, which can feed back to enhance tumor growth resulting in the vicious cycle of bone metastasis. Activated nuclear factor-κB (NF-κB) in breast cancer cells has been shown to play a crucial role in the osteolytic bone metastasis of breast cancer in stimulating osteoclastogenesis. The flavonoid p-hydroxycinnamic acid (HCA) mediates bone anabolic and anti-catabolic effects by stimulating osteoblastic bone formation and suppressing osteoclastic bone resorption. However, the capacity of HCA to ameliorate the negative effects of breast cancer on bone cells has not been investigated. The present study was undertaken to determine the anticancer effects of HCA on MDA-MB-231 human breast cancer bone metastatic cells in?vitro models. Proliferation of MDA-MB?231 cells was suppressed by culture with HCA (10-1000?nM) due to G1 and G2/M phase cell cycle arrest. The suppressive effects of HCA were mediated through signaling pathways that are related to NF-κB, extracellular signal-regulated kinase (ERK), protein kinase?C, calcium signaling, phosphatidylinositol 3-kinase (PI3K) and nuclear transcription activity. HCA was also found to induce death of confluent cancer cells. Furthermore, co-culture with MDA-MB-231 cells suppressed mineralization and stimulated osteoclastogenesis in bone marrow cells. These alterations were prevented by HCA (10-250?nM). The present study demonstrates that HCA possesses anticancer properties in MDA-MB-231 human breast cancer cells and alleviates the negative effects on osteoblastogenesis and osteoclastogenesis in?vitro. HCA may have important applications in the treatment of breast cancer bone metastasis.
机译:肿瘤侵入骨组织与破骨细胞和成骨细胞募集有关,导致生长因子从骨基质中释放出来,这些生长因子可以反馈以增强肿瘤生长,从而导致骨转移的恶性循环。乳腺癌细胞中的活化核因子-κB(NF-κB)已被证明在刺激乳腺癌的破骨性骨转移中起着至关重要的作用。类黄酮对羟基肉桂酸(HCA)通过刺激成骨细胞的骨形成和抑制破骨细胞的骨吸收来介导骨合成代谢和抗分解代谢作用。但是,尚未研究HCA减轻乳腺癌对骨细胞的负面影响的能力。进行本研究以确定HCA在体外模型中对MDA-MB-231人乳腺癌骨转移细胞的抗癌作用。由于G1期和G2 / M期细胞周期停滞,HCA(10-1000ΔnM)培养抑制了MDA-MBΔ231细胞的增殖。 HCA的抑制作用是通过与NF-κB,细胞外信号调节激酶(ERK),蛋白激酶ΔC,钙信号传导,磷脂酰肌醇3-激酶(PI3K)和核转录活性有关的信号传导途径介导的。还发现HCA诱导融合癌细胞死亡。此外,与MDA-MB-231细胞共培养可抑制矿化并刺激骨髓细胞中的破骨细胞生成。通过HCA(10-250?nM)可以防止这些改变。本研究表明,HCA在MDA-MB-231人乳腺癌细胞中具有抗癌特性,并减轻了其对体外成骨细胞生成和破骨细胞生成的负面影响。 HCA在乳腺癌骨转移的治疗中可能具有重要的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号